Literature DB >> 23610735

Two Cases of Adolescents with Paratesticular Rhabdomyosarcoma Inadequately Treated: The Problem of Referral.

Andrea Ferrari1, Cristina Meazza, Marco Vajna de Pava, Carlo Alfredo Clerici, Michela Casanova.   

Abstract

This paper reports on two cases of adolescents with paratesticular embryonal rhabdomyosarcoma completely resected at diagnosis (a pediatric disease potentially curable in more than 90% of cases) and treated at adult facilities with a strategy used for adult soft tissue sarcomas. The final outcome of the two patients was dismal after they received a treatment inconsistent with pediatric protocols. The cases reported here give us a chance to turn the spotlight on a crucial issue-the referral of adolescents with pediatric-type tumors and their access to experienced centers and clinical trials.

Entities:  

Year:  2011        PMID: 23610735      PMCID: PMC3621802          DOI: 10.1089/jayao.2011.0016

Source DB:  PubMed          Journal:  J Adolesc Young Adult Oncol        ISSN: 2156-5333            Impact factor:   2.223


  24 in total

Review 1.  The challenges of clinical trials for adolescents and young adults with cancer.

Authors:  Andrea Ferrari; Michael Montello; Troy Budd; Archie Bleyer
Journal:  Pediatr Blood Cancer       Date:  2008-05       Impact factor: 3.167

2.  Harmonizing adult and pediatric approaches to the treatment of soft-tissue sarcoma.

Authors:  Andrea Ferrari
Journal:  Expert Rev Anticancer Ther       Date:  2009-11       Impact factor: 4.512

3.  Upper age limits for accessing pediatric oncology centers in Italy: a barrier preventing adolescents with cancer from entering national cooperative AIEOP trials.

Authors:  Andrea Ferrari; Maurizio Aricò; Giorgio Dini; Roberto Rondelli; Fulvio Porta
Journal:  Pediatr Hematol Oncol       Date:  2011-06-27       Impact factor: 1.969

Review 4.  Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

Authors:  R B Raney; J R Anderson; F G Barr; S S Donaldson; A S Pappo; S J Qualman; E S Wiener; H M Maurer; W M Crist
Journal:  J Pediatr Hematol Oncol       Date:  2001-05       Impact factor: 1.289

5.  National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation.

Authors:  Archie Bleyer; Michael Montello; Troy Budd; Scott Saxman
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

6.  Adult rhabdomyosarcoma: outcome following multimodality treatment.

Authors:  Darren J Little; Matthew T Ballo; Gunar K Zagars; Peter W T Pisters; Shreyaskumar R Patel; Adel K El-Naggar; Adam S Garden; Robert S Benjamin
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

Review 7.  Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.

Authors:  Andrea Ferrari; Palma Dileo; Michela Casanova; Rossella Bertulli; Cristina Meazza; Lorenza Gandola; Pierina Navarria; Paola Collini; Alessandro Gronchi; Patrizia Olmi; Franca Fossati-Bellani; Paolo G Casali
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

Review 8.  Challenges in the recruitment of adolescents and young adults to cancer clinical trials.

Authors:  Megan E Burke; Karen Albritton; Neyssa Marina
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860

9.  Adolescents with cancer in Italy: entry into the national cooperative paediatric oncology group AIEOP trials.

Authors:  Andrea Ferrari; Elisa Dama; Andrea Pession; Roberto Rondelli; Cristiana Pascucci; Franco Locatelli; Stefano Ferrari; Maurizio Mascarin; Franco Merletti; Giuseppe Masera; Maurizio Aricò; Guido Pastore
Journal:  Eur J Cancer       Date:  2009-01-08       Impact factor: 9.162

10.  Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  D Joshi; James R Anderson; C Paidas; J Breneman; D M Parham; W Crist
Journal:  Pediatr Blood Cancer       Date:  2004-01       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.